There's still time to register for #EBMT26!🩸 Hear from Anna Sureda, the President of @theebmt.bsky.social, who shares insight into this fantastic event & invites you to join: 🎥 👉 buff.ly/oixK5Pq Can't make it to Madrid? You can register to attend virtually instead! Click here: ➡️ buff.ly/ahhtftc

Excitement is building for #EBMT26! 🌟🔜 From 22-25 March 2026, #Madrid 🇪🇸 will host thousands of HCP's and innovators. 🚀 Attend in-person, secure a Day Pass or join virtually and access recordings until 25 April 2026. 🎫 Register now ⬇️ https://www.ebmt.org/annual-meeting/register

EBMT 2026 is around the corner! 🔜 #EBMT26 Join thousands of HCP's in #Madrid 🇪🇸 from 22-25 March 2026. 🤩 📍 Attend in person 🎫 Get a Day Pass 💻 Or join virtually Register here ➡️🔗 https://www.ebmt.org/annual-meeting-2026

We're thrilled to be an official media partner for #EBMT26, and we can't wait to be on-site once again, filming our expert video interviews! 🎥🩸 Interested in joining us there or attending virtually? Click here to register now: ➡️ buff.ly/bWxuru2 #BMTsm #HemOnc #ImmunoOnc @theebmt.bsky.social

Want to find out about the latest updates and advances in transplantation and cellular therapy?🩸 Then you won't want to miss the 52nd Annual Meeting of the EBMT taking place 22–25 March in Madrid, Spain, & online.🇪🇸💻 Register here: ➡️ buff.ly/0fBo0ka #EBMT26 #HemOnc #BMTsm @theebmt.bsky.social

Official Registration to EBMT 2026

Sign up to attend the 52nd Annual Meeting of the EBMT in-person in Madrid or virtually. Get the best rate by registering before the Early Bird deadline on 19 January 2026.

ow.ly

Just one week to go until #CART26 kicks off in Palma de Mallorca, Spain, and online!🇪🇸 💻 Hear from the meeting chair, Annalisa Ruggeri, who encourages you to register for this hybrid meeting: 🎥 buff.ly/poXdp9x Register here: ➡️ buff.ly/LMXQ0qU.. #CARTCell #ImmunoOnc #HemOnc @theebmt.bsky.social

Have you registered for #CART26 yet?🩸 Hear from @alexrampotas.bsky.social, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy: 🎥 buff.ly/WhO2pQl Register here: 👉 buff.ly/NBpWzCH @theebmt.bsky.social

Want to find out about the latest advances in #CARTCell therapy?🩸💉 Register for the EBMT-EHA 8th European CAR T-cell Meeting taking place next month, and stay tuned for our exclusive coverage of this fantastic event!🎥 Click here to register: 👉 buff.ly/kVxJ8jg.. 👈 #CART26 @theebmt.bsky.social

We are thrilled to be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, taking place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸 Want to join us there or attend virtually? Register here: 👉 buff.ly/HFpKa82.. #CARTCell #CART26 @theebmt.bsky.social

In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England. Watch here: 👉 buff.ly/FZdouqO 👈 #CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies. Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei. Watch now: 👉 buff.ly/VJJUbmz #AMLsm #Leusm #Leukemia

At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma. Click here to watch: 🎥 buff.ly/Ut0Ne7p #MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky

Thank you to Ali Taher for speaking with us recently and providing valuable insight into the management of acute complications of #thalassemia that may present to the emergency department. Watch the interview here: 👉 buff.ly/yL0drrc 👈 #Hematology #BloodSky #HemeSky #MedSky

🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies: 👉 buff.ly/BKMPQGT 👈 #CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky

In an interview from #SOHO2025, @krishpatelmd.bsky.social of @scri.com comments on the potential of NK cell-based therapies for B-cell lymphomas. Click here to watch: 👉 buff.ly/jMYSlMT 👈 #LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky

🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities: 👉 buff.ly/MjL0Oku 👈 #CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25

Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma. Watch here: 👉 buff.ly/6GUNfkY 👈 #ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky

What are the key risk factors for the development of bone disease in patients with #thalassemia? 🩸🦴 Julian Waung provided insight into this in a recent interview – watch here: 👉 buff.ly/Oe2kknT 👈 #Hematology #BloodSky #HemeSky #MedSky

At #iwNHL25, Alexey Danilov of @cityofhope.bsky.social and Meghan Thompson of @mskcancercenter.bsky.social sat down to provide an update on BTK-targeting therapies in non-Hodgkin #lymphoma and CLL.🩸 This is a discussion you don't want to miss! Click here: 🎥 buff.ly/t3TZTiT #LYMsm #HemOnc

The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉 We recently had the pleasure of speaking to Helen Parry to find out more about the study: 🎥 buff.ly/j1K0VV8 #CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc

Check out this fantastic discussion with #lymphoma experts Martin Dreyling & Georg Hess, who discuss key advances in MCL treatment. Topics covered: 🔸 The TRIANGLE trial 🔸 The role of novel agents 🔸 Treatment approaches for frontline and relapsed disease 👉 buff.ly/QbNZjR2 #LymSM #HemOnc

🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY: 👉 buff.ly/paPH5vx 👈 #CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky

It was fantastic to catch up with @jmikhaelmd.bsky.social at #SOHO2025 to gain insight into areas of consensus & controversy in the current & future management of R/R #MultipleMyeloma!🩸 Watch the interview here: 👉 buff.ly/7AoA6tc 👈 #MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease. Watch here: 👉 buff.ly/HbJTfmF 👈 #AMLsm #Leusm #Leukemia #HemOnc #BloodSky

It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings. Watch the interview here: 🎥 buff.ly/sZGLLe2 #CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

We recently had the pleasure of interviewing the lovely Payal Desai to hear about several topics in the field of #SickleCellDisease, including the potential of the six-minute walk test as a prognostic tool. 🚶 Learn more here: 👉 buff.ly/iMa7wAa #Hematology #BloodSky #HemeSky #MedSky

Want to gain insight into the use of bispecific antibodies & other immunotherapies in early lines of treatment for #NonHodgkinLymphoma?🩸 Check out our discussion from #iwNHL25, with leading experts @DocHutchings, @elizabeth_budde, Lorenzo Falchi, & Sameh Gaballa: 🎥 buff.ly/CPiM5kC #LYMsm #HemOnc

In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma. Click to watch: 👉 buff.ly/RVZjPoG 👈 #CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky

What should the optimal pre-transfusion hemoglobin target be in patients with thalassemia? 🤔🩸 We caught up with Maria Domenica Cappellini recently to find out! Click here to watch the interview: 🎥 👉 buff.ly/B8HDjTL #Thalassemia #Hematology #BloodSky #HemeSky #MedSky

#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product: 🎥 buff.ly/s2zXiCa #ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky